Third Party Medical Journal Articles

• Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19) (5 May 2020)

• Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 (1 May 2020)

• Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 (1 May 2020)

• Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 (1 May 2020)

• Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 (17 April 2020)

• COVID-19, ACE2, and the Cardiovascular Consequences. Andrew M. South, Debra I. Diz, and Mark C. Chappell (31 March 2020)

• Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection. David S. Fedson, Steven M. Opal and Ole Martin Rordam (20 March 2020)

• SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Markus Hoffmann, Hannah Kleine Weber, Simon Schroeder, et al. (5 March 2020)

• Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target (3 March 2020)

• Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics (25 February 2020)

• ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism (7 February 2020)

• Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 aftervascular balloon injury in rats (18 June 2013)

• Renin–angiotensin system in human coronavirus pathogenesis (1 March 2010)

• Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures (1 February 2010)

• A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury (10 July 2005)